Hip OsteoarthritisNCT06768541
Subsidence of Short Stem THA With DORR Type C
An observational study of Hip Osteoarthritis and Short Stem Prosthesis, run by Krankenhaus Barmherzige Schwestern Linz at 1 site in Austria.
Trial summary
Total hip arthroplasty (THA) is a widely accepted procedure for the treatment of end-stage hip osteoarthritis. Neck preserving short stems have gained popularity in recent years, as they aim to preserve proximal femoral bone stock and enable a more physiological load transfer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hip Osteoarthritis, Short Stem Prosthesis, Total Hip Arthroplasty (THA)
- What is being tested?
- THA using a short stem
- Type of treatment
- Surgery or procedure
- How many people
- 108 participants
- Where
- 1 siteAustria
- Study dates
- 1 Jan 2023to 31 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 108 patients were eligible, of which 55 underwent routine follow-ups. Complete data was available from 44 patients. 22 patients each were male and female. Mean age at surgery was 68.3 years. Mean BMI was 27.9 kg/m2
Who may be able to join
- THA using Optimys short stem from 1.1.2018 bis 31.12.2020 in the institution.
- Typ C Femur according to Dorr
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Short Stem Total Hip Arthroplasty in Patients With DORR Type C Femur Configuration: Measured Subsidence
Total hip arthroplasty (THA) is a widely accepted procedure for the treatment of end-stage hip osteoarthritis. Neck preserving short stems have gained popularity in recent years, as they aim to preserve proximal femoral bone stock and enable a more physiological load transfer. However, the use of these stems in patients with specific femoral deformities, such as DORR Type C femurs, can present unique challenges. DORR Type C femurs are characterized by decreased cortical bone thickness and increased medullary canal width, which can impact the fit and stability of the femoral stem component. Short stem total hip arthroplasty has emerged as a potential solution for these patients, as it aims to preserve proximal femoral bone stock and improve load transfer to the surrounding bone. This study seeks to investigate the measured subsidence of short stem total hip arthroplasty in patients with DORR Type C femur configuration and the clinical outcomes associated with this approach.
Read the detailed description
In hip arthroplasty, short stems represent a key advancement in the field of bone-preserving surgical techniques. Due to the relatively rapid establishment of short stems, the data situation is lagging behind in some areas, resulting in uncertainties in the indication in certain cases. One of these cases is proximal femurs with a Dorr type C configuration. This bone characteristic complicates the implantation of stems due to a thin cortical bone and a wide femoral canal and has been shown to lead to an increased complication rate. The aim of this study is to evaluate the clinical and radiological outcome of short stem implantation in Dorr type C femur. The study will include all patients who underwent implantation of the "Optimys" short stem from Mathys between January 1, 2018 and December 31, 2020 at the hospital Ordensklinikum Linz Barmherzige Schwestern. In addition, patients must have a type C femur according to Dorr. During a follow-up period of at least two years, the Harris Hip Score, the UCLA Activity-level Scale and the Singh Index are used to evaluate the clinical course. Radiological evaluation is carried out using pre- and postoperative X-rays, which together enable an EBRA-FCA.
A statement on the migration behavior of the cementless implanted short stem in Dorr type C femur is expected. To date, it has been controversially discussed whether a Dorr type C femur provides enough structural support to achieve good primary stability for a cementless implanted short stem with tapered-wedge design. If this were not the case, the excessive migration behavior would lead to subsidence and subsequently to aseptic stem loosening and even complete failure of the prosthesis.
- Being tested
- THA using a short stem
- Medical subject headings
- Osteoarthritis, Hip
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
THA using a short stemProcedure or surgery
Total Hip Arthroplasty using a collarless, triple-tapered cementless short stem (Optimys, produced by Mathys).
| Study group | Role | What they receive |
|---|---|---|
| Dorr C Hip | Patients who received short stem THA with a Dorr C configuration of the femur Receives: Procedure: THA using a short stem |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stem Subsidence
Subsidence of the femoral stem, measured in mm
Measured: 2 years
Secondary outcomes (3)
HHS
Harris Hip Score, 0-100 points. 0 points indicate worst, 100 points indicate best outcome.
Measured: 2 years
OHS
Oxford Hip Score, 0-48points 0 points indicate worst, 48 points indicate best outcome.
Measured: 2 years
SF-12
Short Form 12, 12 questions with 0-100 points. 0 points indicate worst, 100 points indicate best outcome. Norm-Based-Scoring is used.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2025
- Study start1 Jan 2023
- Primary completion31 Jul 2024
- Study completion31 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 108 participants (actual)
Sponsor and investigators
- Lead sponsor
- Krankenhaus Barmherzige Schwestern Linz
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06768541
- Sponsor's protocol ID
- EK1330/2022
- Status last verified
- Mar 2026
- First submitted
- 1 Dec 2024
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Short Stem Total Hip Arthroplasty in Patients With DORR Type C Femur Configuration: Measured Subsidence
- ClinicalTrials.gov ID
- NCT06768541
- Acronym / sponsor ID
- EK1330/2022
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 108 participants (actual)
- Lead sponsor
- Krankenhaus Barmherzige Schwestern LinzUniversity, hospital or other
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 31 Jul 2024 (actual)
- Study completion
- 31 Mar 2025 (actual)
- First posted
- 10 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Total hip arthroplasty (THA) is a widely accepted procedure for the treatment of end-stage hip osteoarthritis. Neck preserving short stems have gained popularity in recent years, as they aim to preserve proximal femoral bone stock and enable a more physiological load transfer. However, the use of these stems in patients with specific femoral deformities, such as DORR Type C femurs, can present unique challenges. DORR Type C femurs are characterized by decreased cortical bone thickness and increased medullary canal width, which can impact the fit and stability of the femoral stem component. Short stem total hip arthroplasty has emerged as a potential solution for these patients, as it aims to preserve proximal femoral bone stock and improve load transfer to the surrounding bone. This study seeks to investigate the measured subsidence of short stem total hip arthroplasty in patients with DORR Type C femur configuration and the clinical outcomes associated with this approach.
Detailed description
In hip arthroplasty, short stems represent a key advancement in the field of bone-preserving surgical techniques. Due to the relatively rapid establishment of short stems, the data situation is lagging behind in some areas, resulting in uncertainties in the indication in certain cases. One of these cases is proximal femurs with a Dorr type C configuration. This bone characteristic complicates the implantation of stems due to a thin cortical bone and a wide femoral canal and has been shown to lead to an increased complication rate. The aim of this study is to evaluate the clinical and radiological outcome of short stem implantation in Dorr type C femur. The study will include all patients who underwent implantation of the "Optimys" short stem from Mathys between January 1, 2018 and December 31, 2020 at the hospital Ordensklinikum Linz Barmherzige Schwestern. In addition, patients must have a type C femur according to Dorr. During a follow-up period of at least two years, the Harris Hip Score, the UCLA Activity-level Scale and the Singh Index are used to evaluate the clinical course. Radiological evaluation is carried out using pre- and postoperative X-rays, which together enable an EBRA-FCA.
A statement on the migration behavior of the cementless implanted short stem in Dorr type C femur is expected. To date, it has been controversially discussed whether a Dorr type C femur provides enough structural support to achieve good primary stability for a cementless implanted short stem with tapered-wedge design. If this were not the case, the excessive migration behavior would lead to subsidence and subsequently to aseptic stem loosening and even complete failure of the prosthesis.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dorr C Hip | – | Procedure: THA using a short stemPatients who received short stem THA with a Dorr C configuration of the femur |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 108 patients were eligible, of which 55 underwent routine follow-ups. Complete data was available from 44 patients. 22 patients each were male and female. Mean age at surgery was 68.3 years. Mean BMI was 27.9 kg/m2
Key inclusion criteria (2 listed)
- THA using Optimys short stem from 1.1.2018 bis 31.12.2020 in the institution.
- Typ C Femur according to Dorr
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| THA using a short stemTotal Hip Arthroplasty using a collarless, triple-tapered cementless short stem (Optimys, produced by Mathys). | Procedure or surgery | Dorr C Hip |
Primary outcome
Stem Subsidence
Time frame: 2 years
Subsidence of the femoral stem, measured in mm
3 secondary outcomes
HHS
Time frame: 2 years
OHS
Time frame: 2 years
SF-12
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hip Osteoarthritis
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Osteoarthritis, Hip, Hip Osteoarthritis
Recruiting
Effects of EDUcation and EXercise Compared to Education Alone on Clinical and Physiological Outcomes in Patients With Hip Osteoarthritis
Hip Osteoarthritis
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Osteoarthritis and Short Stem Prosthesis, run by Krankenhaus Barmherzige Schwestern Linz at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stem Subsidence (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.